| ²é¿´: 1111 | »Ø¸´: 2 | ||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | ||
a116542ͳæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇëÎʱûÏ©ëæÔÚÒ©ÎïÖк¬Á¿ÏÞ¶ÈÊǶàÉÙ£¿ ÒÑÓÐ1È˲ÎÓë
|
|
ËÓÐÏà¹Ø×ÊÁÏ£¬°ï棬Íò·Ö¸Ðл![]() |
» ²ÂÄãϲ»¶
SPguide®£ºÐ¡ÊóÌåÄÚÆ¢ÔàתȾµÄÒ»¼ü½â¾ö·½°¸
ÒѾÓÐ0È˻ظ´
¸ßЧ·Î°ÐÏòRNAתȾ£¬¼ÓËٷβ¿RNAÒ©Î↑·¢
ÒѾÓÐ2È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ138È˻ظ´
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
a116542
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 42.6
- Ìû×Ó: 21
- ÔÚÏß: 21.6Сʱ
- ³æºÅ: 2025707
- ×¢²á: 2012-09-24
- רҵ: ·ÖÎöÒÇÆ÷ÓëÊÔ¼Á
3Â¥2016-05-30 11:36:06
jasonscott
Ìú³æ (ÕýʽдÊÖ)
- DRDEPI: 3
- Ó¦Öú: 65 (³õÖÐÉú)
- ½ð±Ò: 2573
- ºì»¨: 9
- Ìû×Ó: 533
- ÔÚÏß: 285.5Сʱ
- ³æºÅ: 809179
- ×¢²á: 2009-07-15
- רҵ: ÓлúºÏ³É
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
¸ù¾ÝADDENDUM TO ICH M7: ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENIC RISK APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES M7(R1)¹«¿ªµÄ¶¾ÀíÊý¾Ý£¬±ûÏ©ëæµÄPDEÊÇ6΢¿Ë/ÈÕ¡£Äã¸ù¾ÝÒ©ÎïµÄÈÕ·þÓüÁÁ¿À´ÍÆËãÔÊÐíÏ޶Ȱɡ£ |
2Â¥2016-05-27 15:56:54















»Ø¸´´ËÂ¥